BPC
KNSA icon

Bryce Point Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bryce Point Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$265K Buy
+6,831
New +$222K 0.32% 147

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bryce Point Capital's KNSA Position: Q3 2025 in Review

Bryce Point Capital opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q3 2025: 6,831 shares worth $265K. The stake represents 0.32% of the portfolio and ranks #147 among its holdings.

204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

  • Bryce Point Capital held 6,831 shares of Kiniksa Pharmaceuticals worth $265K as of Q3 2025.
  • Kiniksa Pharmaceuticals was a new Bryce Point Capital position in Q3 2025.
  • Kiniksa Pharmaceuticals made up 0.32% of Bryce Point Capital's portfolio in Q3 2025, its #147 holding.
  • 204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.